IONS catalyst calendar

IONIS PHARMACEUTICALS INC

Upcoming catalysts
18
Cash runway
7.8 months
Cash & investments
$2055M
Phase 3 programs
22

IONIS PHARMACEUTICALS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) on December 15, 2026. There are 18 upcoming events on record.

Cash runway is approximately 7.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 94 concluded trials, 91% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
December 15, 2026 A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Trial Milestone Phase 3
December 26, 2026 est. Next quarterly earnings (projected) Earnings —
March 15, 2027 CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) Trial Milestone Phase 3
April 15, 2027 PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 Trial Milestone Phase 1/Phase 2
June 15, 2027 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen Trial Milestone Phase 3
August 15, 2027 REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome Trial Milestone Phase 3
September 15, 2027 A Study to Assess the Safety, Tolerability and Efficacy of ION775 Trial Milestone Phase 2
September 15, 2027 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) Trial Milestone Phase 1
September 15, 2027 ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS) Trial Milestone Phase 1/Phase 2
February 15, 2028 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) Trial Milestone Phase 3
May 15, 2028 CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS) Trial Milestone Phase 3
June 15, 2028 Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD) Trial Milestone Phase 1
March 15, 2029 HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome Trial Milestone Phase 1/Phase 2
June 15, 2029 Donidalorsen Treatment in Children With Hereditary Angioedema Trial Milestone Phase 3
August 15, 2029 A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Trial Milestone Phase 3
August 15, 2029 An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Trial Milestone Phase 3
August 15, 2030 A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants Trial Milestone Phase 3
December 15, 2030 ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome Trial Milestone Phase 1/Phase 2

Track IONS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open IONS in the tracker

Recent history

DateEventTypePhase
September 23, 2026 8-K filed: Reg FD disclosure, Other event Filing —
September 4, 2026 8-K filed: Reg FD disclosure, Other event Filing —
September 4, 2026 8-K filed: Reg FD disclosure, Other event Filing —
July 29, 2026 Quarterly results filed (8-K) Earnings —
July 10, 2026 8-K filed: Reg FD disclosure Filing —
July 9, 2026 8-K filed: Reg FD disclosure, Other event Filing —
June 24, 2026 8-K filed: Reg FD disclosure, Other event Filing —
June 17, 2026 FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) Trial Milestone Phase 3
June 12, 2026 8-K filed: Other event Filing —
June 8, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 28, 2026 8-K filed: Reg FD disclosure, Other event Filing —
April 29, 2026 Quarterly results filed (8-K) Earnings —
April 21, 2026 8-K filed: Reg FD disclosure, Other event Filing —
March 25, 2026 CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Trial Milestone Phase 3
March 9, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
February 25, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 Quarterly results filed (8-K) Earnings —
January 7, 2026 8-K filed: Reg FD disclosure, Other event Filing —
December 3, 2025 Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) Trial Milestone Phase 1
November 17, 2025 8-K filed: Material agreement, Other event Corporate —
November 10, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 3, 2025 8-K/A filed: Material agreement Corporate —
October 29, 2025 Quarterly results filed (8-K) Earnings —
September 22, 2025 8-K filed: Reg FD disclosure, Other event Filing —
September 2, 2025 8-K filed: Reg FD disclosure, Other event Filing —
August 22, 2025 A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) Trial Milestone Phase 3
August 21, 2025 8-K filed: Reg FD disclosure, Other event Filing —
July 30, 2025 Quarterly results filed (8-K) Earnings —
June 26, 2025 A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera Trial Milestone Phase 2
June 12, 2025 8-K filed: Leadership change Corporate —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.